Extracellular vesicles from mesenchymal stromal cells: Therapeutic perspectives for targeting senescence in osteoarthritis

Adv Drug Deliv Rev. 2021 Aug:175:113836. doi: 10.1016/j.addr.2021.113836. Epub 2021 Jun 22.

Abstract

Osteoarthritis (OA) is a common age-related disease that correlates with a high number of senescent cells in joint tissues. Senescence has been reported to be one of the main drivers of OA pathogenesis, in particular via the release of senescence-associated secretory phenotype (SASP) factors. SASP factors are secreted as single molecules and/or packaged within extracellular vesicles (EVs), thereby contributing to senescent phenotype dissemination. Targeting senescent cells using senolytics or senomorphics has therefore been tested and improvement of OA-associated features has been reported in murine models. Mesenchymal stromal cells (MSCs) and their derived EVs (MSC-EVs) are promising treatments for OA, exerting pleiotropic functions by producing a variety of factors. However, functions of MSCs and MSC-EVs are affected by aging. In this review, we discuss on the impact of the senescent environment on functions of aged MSC-EVs and on the anti-aging properties of MSC-EVs in the context of OA.

Keywords: Aging; Extracellular vesicle; Mesenchymal stromal cell; Osteoarthritis; Regenerative medicine; Senescence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging / drug effects*
  • Aging / pathology
  • Animals
  • Extracellular Vesicles / pathology*
  • Humans
  • Mesenchymal Stem Cells / pathology*
  • Osteoarthritis / drug therapy
  • Osteoarthritis / pathology*
  • Senotherapeutics / therapeutic use

Substances

  • Senotherapeutics